Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2017 - 2025)

Historic Return on Capital Employed for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to 0.6%.

  • Ultragenyx Pharmaceutical's Return on Capital Employed fell 1800.0% to 0.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.6%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.46% for FY2024, which is 0.0% changed from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Return on Capital Employed stood at 0.6% for Q3 2025, which was down 1800.0% from 0.5% recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Return on Capital Employed peaked at 0.2% during Q1 2021, and registered a low of 0.61% during Q2 2023.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.46% (2024), whereas its average is 0.44%.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Return on Capital Employed skyrocketed by 2500bps in 2021 and then tumbled by -2100bps in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Return on Capital Employed (Quarter) stood at 0.29% in 2021, then tumbled by -70bps to 0.49% in 2022, then dropped by -7bps to 0.53% in 2023, then increased by 13bps to 0.46% in 2024, then plummeted by -31bps to 0.6% in 2025.
  • Its Return on Capital Employed stands at 0.6% for Q3 2025, versus 0.5% for Q2 2025 and 0.46% for Q1 2025.